Karin Badel

2.1k total citations
27 papers, 1.6k citations indexed

About

Karin Badel is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Karin Badel has authored 27 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 9 papers in Oncology and 8 papers in Immunology. Recurrent topics in Karin Badel's work include Hematopoietic Stem Cell Transplantation (17 papers), Multiple Myeloma Research and Treatments (12 papers) and Acute Myeloid Leukemia Research (10 papers). Karin Badel is often cited by papers focused on Hematopoietic Stem Cell Transplantation (17 papers), Multiple Myeloma Research and Treatments (12 papers) and Acute Myeloid Leukemia Research (10 papers). Karin Badel collaborates with scholars based in United States, Canada and Germany. Karin Badel's co-authors include Gary Calandra, Gary Calandra, Gary Bridger, John F. DiPersio, Jane L. Liesveld, Daniel J. Weisdorf, Neal Flomenberg, Steven M. Devine, David H. Vesole and R. T. MacFarland and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Karin Badel

27 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karin Badel United States	14	1.0k	766	623	296	203	27	1.6k
Gary Calandra United States	15	1.1k 1.1×	693 0.9×	500 0.8×	307 1.0×	199 1.0×	41	1.7k
Paulo Vidal Campregher Brazil	12	429 0.4×	569 0.7×	950 1.5×	323 1.1×	188 0.9×	57	1.7k
Ruth Seggewiss Germany	16	722 0.7×	374 0.5×	567 0.9×	322 1.1×	384 1.9×	26	1.4k
Baldev Vasir United States	20	363 0.4×	762 1.0×	931 1.5×	735 2.5×	42 0.2×	42	1.7k
Mariagrazia Michieli Italy	24	599 0.6×	1.2k 1.5×	162 0.3×	527 1.8×	376 1.9×	107	1.9k
Hong Zheng United States	22	421 0.4×	864 1.1×	1.1k 1.7×	602 2.0×	65 0.3×	69	2.0k
Alexandre Theocharides Switzerland	21	785 0.8×	232 0.3×	472 0.8×	756 2.6×	892 4.4×	42	1.7k
Friedrich Schuening United States	21	617 0.6×	198 0.3×	277 0.4×	195 0.7×	174 0.9×	61	1.0k
Thorsten Graef United States	23	876 0.9×	538 0.7×	651 1.0×	671 2.3×	627 3.1×	61	2.0k
C. Gattringer Austria	12	216 0.2×	408 0.5×	234 0.4×	342 1.2×	118 0.6×	45	939

Countries citing papers authored by Karin Badel

Since Specialization

Citations

This map shows the geographic impact of Karin Badel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Badel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Badel more than expected).

Fields of papers citing papers by Karin Badel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Badel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Badel. The network helps show where Karin Badel may publish in the future.

Co-authorship network of co-authors of Karin Badel

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Badel. A scholar is included among the top collaborators of Karin Badel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Badel. Karin Badel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Flomenberg, Neal, Raymond L. Comenzo, Karin Badel, & Gary Calandra. (2010). Plerixafor (Mozobil®) Alone to Mobilize Hematopoietic Stem Cells from Multiple Myeloma Patients for Autologous Transplantation. Biology of Blood and Marrow Transplantation. 16(5). 695–700. 23 indexed citations

Stiff, Patrick J., Ivana N. Micallef, Philip L. McCarthy, et al.. (2009). Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated Patient. Biology of Blood and Marrow Transplantation. 15(2). 249–256. 86 indexed citations

Dugan, Michael J., Richard T. Maziarz, Jack W. Singer, et al.. (2009). Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplantation. 45(1). 39–47. 103 indexed citations

Früehauf, Stefan, Gerhard Ehninger, Kai Hübel, et al.. (2009). Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplantation. 45(2). 269–275. 50 indexed citations

Moyle, Graeme, Edwin DeJesus, Marta Boffito, et al.. (2009). Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4‐Tropic HIV Type 1. Clinical Infectious Diseases. 48(6). 798–805. 60 indexed citations

Cashen, Amanda F., Feng Gao, Gary Calandra, et al.. (2008). A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 14(11). 1253–1261. 107 indexed citations

Gazitt, Yair, César O. Freytes, Cagla Akay, Karin Badel, & Gary Calandra. (2007). Improved Mobilization of Peripheral Blood CD34 ⁺ Cells and Dendritic Cells by AMD3100 plus Granulocyte–Colony-Stimulating Factor in Non-Hodgkin's Lymphoma Patients. Stem Cells and Development. 16(4). 657–666. 43 indexed citations

Calandra, Gary, John M. McCarty, Joseph P. McGuirk, et al.. (2007). AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplantation. 41(4). 331–338. 221 indexed citations

MacFarland, R. T., et al.. (2007). Pharmacokinetics of Plerixafor (AMD3100) in Volunteers with Renal Impairment.. Blood. 110(11). 2878–2878. 5 indexed citations

10.

Calandra, Gary, et al.. (2007). 15: AMD3100 plus G-CSF mobilizes the majority of non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM), and Hodgkin’s disease (HD) patients who failed prior mobilization with other regimens. Biology of Blood and Marrow Transplantation. 13(2). 8–8. 4 indexed citations

11.

Smith, Clayton A., et al.. (2006). AMD3100 with G-CSF for Autologous Peripheral Blood Progenitor Cell (PBPC) Mobilization in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM): Mobilization, Engraftment, and Pharmacokinetics (PK).. Blood. 108(11). 3383–3383. 5 indexed citations

12.

Calandra, Gary, et al.. (2006). AMD3100 Plus G-CSF Mobilizes the Majority of Non-Hodgkin’s Lymphoma (NHL), Multiple Myeloma (MM), and Hodgkin’s Disease (HD) Patients Who Failed Prior Mobilization with Other Regimens.. Blood. 108(11). 5218–5218. 2 indexed citations

13.

Stiff, Patrick J., Philip L. McCarthy, Margarida Magalhaes‐Silverman, et al.. (2005). AMD3100 plus G-CSF rapidly mobilizes hematopoietic progenitor cells in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM), including those traditionally considered “poor mobilizers”. Biology of Blood and Marrow Transplantation. 11(2). 92–92. 1 indexed citations

14.

Lack, Nathan A., David C. Dale, Gary Calandra, et al.. (2005). A pharmacokinetic-pharmacodynamic model for the mobilization of CD34 hematopoietic progenitor cells by AMD3100. Clinical Pharmacology & Therapeutics. 77(5). 427–436. 61 indexed citations

15.

Liles, W. Conrad, Elin Rodger, Hal E. Broxmeyer, et al.. (2005). Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 45(3). 295–300. 177 indexed citations

16.

McGuirk, Joseph P., et al.. (2005). AMD3100 Plus G-CSF Use in Proven Poor Mobilizers in a Compassionate Use Protocol (CUP).. Blood. 106(11). 154–154. 3 indexed citations

17.

Devine, Steven M., Jesper Bonde, David A. Hess, et al.. (2004). A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.. Blood. 104(11). 3341–3341. 14 indexed citations

18.

Hendrix, Craig W., Ann C. Collier, Michael M. Lederman, et al.. (2004). Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 37(2). 1253–1262. 284 indexed citations

19.

Devine, Steven M., Neal Flomenberg, David H. Vesole, et al.. (2004). Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 22(6). 1095–1102. 327 indexed citations

20.

Gazitt, Yair, César O. Freytes, Cagla Akay, et al.. (2004). Improved Mobilization of CD34+ Peripheral Blood Stem Cells (PBSC) and Dendritic Cells (DCs) by AMD-3100 (AMD) in Hard to Mobilize Non-Hodgkin’s Lymphoma (NHL) Patients (pts) Mobilized with Standard Dose of G-CSF.. Blood. 104(11). 2856–2856. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact